Published in Nature on February 10, 2011
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell (2012) 4.52
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature (2012) 3.92
The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) (2013) 3.82
A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform (2013) 3.60
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics (2012) 3.21
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet (2014) 2.72
Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev (2012) 2.67
High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol (2011) 2.63
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
The expanding scope of DNA sequencing. Nat Biotechnol (2012) 2.57
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet (2012) 2.45
Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. Genome Res (2013) 2.43
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29
Discovery of CTCF-sensitive Cis-spliced fusion RNAs between adjacent genes in human prostate cells. PLoS Genet (2015) 2.29
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep (2014) 2.27
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
End-joining, translocations and cancer. Nat Rev Cancer (2013) 2.13
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol (2011) 2.11
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Diverse mechanisms of somatic structural variations in human cancer genomes. Cell (2013) 2.00
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci U S A (2011) 1.99
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Estimation of rearrangement phylogeny for cancer genomes. Genome Res (2011) 1.91
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res (2012) 1.82
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Genome sequencing and cancer. Curr Opin Genet Dev (2012) 1.68
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell (2013) 1.68
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol (2013) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev (2013) 1.61
Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet (2014) 1.60
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet (2014) 1.58
Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics. J Pathol Inform (2012) 1.58
Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood (2014) 1.55
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet (2004) 9.57
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
CHD5 is a tumor suppressor at human 1p36. Cell (2007) 4.90
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature (2009) 4.13
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem (2001) 3.27
Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol (2002) 2.93
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol (2008) 2.19
BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem (2006) 2.03
Hypermutability of damaged single-strand DNA formed at double-strand breaks and uncapped telomeres in yeast Saccharomyces cerevisiae. PLoS Genet (2008) 2.00
Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One (2009) 1.68
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Paired-end mapping reveals extensive structural variation in the human genome. Science (2007) 30.46
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87